StreetInsider.com News Articles

bioAffinity Technologies shows asthma therapy matching technology

Tue, 03 Mar 2026 08:31:27 +0000

bioAffinity Technologies Inc. (NASDAQ: BIAF) presented research demonstrating its diagnostic platform's ability to identify drug antibody receptors in sputum for asthma therapies at the American Academy of Allergy, Asthma and Immunology annual meeting in Philadelphia on March 1.

The research showed the technology can identify receptors for dupilumab, a therapy for asthma and chronic obstructive pulmonary disease, and benralizumab, another asthma treatment. William Bauta, the company's chief science officer, presented the poster titled "Sputum as a Diagnostic Tool for the Treatment of Asthma."

The San Antonio-based biotechnology company is developing clinical diagnostics aimed at helping physicians match asthma and COPD patients with

bioAffinity Technologies shows asthma therapy matching technology

Tue, 03 Mar 2026 08:31:27 +0000

The San Antonio-based biotechnology company is developing clinical diagnostics aimed at helping physicians match asthma and COPD patients with

bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients

Tue, 03 Mar 2026 08:30:00 +0000

Poster presented to medical and drug industry conferees at prestigious American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

Research demonstrates the technology’s ability to identify drug antibody receptors in sputum for two leading asthma therapies

SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced the presentation of a new scientific poster reporting on the ability of the Company’s innovative diagnostic approach to identify antibody drug receptors in sputum, including receptors for dupilumab, a leading therapy for asthma and

bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients

Tue, 03 Mar 2026 08:30:00 +0000

Poster presented to medical and drug industry conferees at prestigious American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

Research demonstrates the technology’s ability to identify drug antibody receptors in sputum for two leading asthma therapies

bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients

Tue, 03 Mar 2026 08:30:00 +0000

Poster presented to medical and drug industry conferees at prestigious American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

Research demonstrates the technology’s ability to identify drug antibody receptors in sputum for two leading asthma therapies

bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients

Tue, 03 Mar 2026 08:30:00 +0000

Poster presented to medical and drug industry conferees at prestigious American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

Research demonstrates the technology’s ability to identify drug antibody receptors in sputum for two leading asthma therapies

bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients

Tue, 03 Mar 2026 08:30:00 +0000

Poster presented to medical and drug industry conferees at prestigious American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

Research demonstrates the technology’s ability to identify drug antibody receptors in sputum for two leading asthma therapies

bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients

Tue, 03 Mar 2026 08:30:00 +0000

Poster presented to medical and drug industry conferees at prestigious American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

Research demonstrates the technology’s ability to identify drug antibody receptors in sputum for two leading asthma therapies

bioAffinity Technologies starts lung cancer test validation study

Wed, 25 Feb 2026 08:31:20 +0000

bioAffinity Technologies Inc. (NASDAQ: BIAF) announced a validation study with Brooke Army Medical Center to test its CyPath Lung diagnostic on sputum samples collected through deep suction procedures.

The study will enroll 30-50 patients undergoing routine tracheal or bronchial suctioning, with results expected by mid-2026. The research aims to validate whether the CyPath Lung test can analyze suctioned sputum samples collected during bronchoscopy and other procedures, potentially expanding sample collection options beyond the current at-home collection method.

"The ability to use CyPath Lung to analyze suctioned sputum collected during bronchoscopy and other procedures would leverage samples that we are already obtaining," said

bioAffinity Technologies starts lung cancer test validation study

Wed, 25 Feb 2026 08:31:20 +0000

"The ability to use CyPath Lung to analyze suctioned sputum collected during bronchoscopy and other procedures would leverage samples that we are already obtaining," said

bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test

Wed, 25 Feb 2026 08:30:00 +0000

Validating sample collection by deep suction has potential to accelerate and expand adoption of CyPath® Lung

SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced a new study with Brooke Army Medical Center (BAMC) to validate the clinical utility of using the CyPath® Lung diagnostic test to assess sputum samples obtained by tracheal and bronchial suctioning for early detection of lung cancer.

The study is designed to enroll approximately 30-50 patients undergoing routine tracheal or bronchial suctioning, with results from the

bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test

Wed, 25 Feb 2026 08:30:00 +0000

Validating sample collection by deep suction has potential to accelerate and expand adoption of CyPath® Lung

SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced a new study with Brooke Army Medical Center (BAMC) to validate the clinical utility of using the CyPath® Lung diagnostic test to assess sputum samples obtained by tracheal and bronchial suctioning for early detection of lung cancer.

The study is designed to enroll approximately 30-50 patients undergoing routine tracheal or bronchial suctioning, with results from the

bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test

Wed, 25 Feb 2026 08:30:00 +0000

Validating sample collection by deep suction has potential to accelerate and expand adoption of CyPath® Lung

SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced a new study with Brooke Army Medical Center (BAMC) to validate the clinical utility of using the CyPath® Lung diagnostic test to assess sputum samples obtained by tracheal and bronchial suctioning for early detection of lung cancer.

The study is designed to enroll approximately 30-50 patients undergoing routine tracheal or bronchial suctioning, with results from the

bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test

Wed, 25 Feb 2026 08:30:00 +0000

Validating sample collection by deep suction has potential to accelerate and expand adoption of CyPath® Lung

SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced a new study with Brooke Army Medical Center (BAMC) to validate the clinical utility of using the CyPath® Lung diagnostic test to assess sputum samples obtained by tracheal and bronchial suctioning for early detection of lung cancer.

The study is designed to enroll approximately 30-50 patients undergoing routine tracheal or bronchial suctioning, with results from the

bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test

Wed, 25 Feb 2026 08:30:00 +0000

Validating sample collection by deep suction has potential to accelerate and expand adoption of CyPath® Lung

SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced a new study with Brooke Army Medical Center (BAMC) to validate the clinical utility of using the CyPath® Lung diagnostic test to assess sputum samples obtained by tracheal and bronchial suctioning for early detection of lung cancer.

The study is designed to enroll approximately 30-50 patients undergoing routine tracheal or bronchial suctioning, with results from the

bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test

Wed, 25 Feb 2026 08:30:00 +0000

Validating sample collection by deep suction has potential to accelerate and expand adoption of CyPath® Lung

SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced a new study with Brooke Army Medical Center (BAMC) to validate the clinical utility of using the CyPath® Lung diagnostic test to assess sputum samples obtained by tracheal and bronchial suctioning for early detection of lung cancer.

The study is designed to enroll approximately 30-50 patients undergoing routine tracheal or bronchial suctioning, with results from the

bioAffinity's CyPath Lung test helps avoid biopsy in elderly patient case

Thu, 19 Feb 2026 11:01:33 +0000

bioAffinity Technologies Inc. (NASDAQ: BIAF) released a case study showing how its CyPath Lung diagnostic test helped avoid an invasive biopsy procedure for a 79-year-old patient with a suspicious lung nodule.

The patient, a smoker with chronic obstructive pulmonary disease and coronary heart disease, underwent low-dose computed tomography screening in June 2025. The scan revealed a spiculated nodule approximately half an inch in size in the right lung. Spiculated nodules typically raise malignancy concerns due to their irregular appearance.

The CyPath Lung test returned a negative result, indicating unlikely malignancy and supporting a surveillance approach rather than immediate biopsy. A follow-up scan

bioAffinity's CyPath Lung test helps avoid biopsy in elderly patient case

Thu, 19 Feb 2026 11:01:33 +0000

The CyPath Lung test returned a negative result, indicating unlikely malignancy and supporting a surveillance approach rather than immediate biopsy. A follow-up scan

New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer

Thu, 19 Feb 2026 11:00:00 +0000

CyPath® Lung test supported recommendation for surveillance strategy, rather than subjecting elderly patient to an invasive, risky and costly biopsy procedure

Despite a suspicious nodule during a low-dose CT scan, a repeat scan showed no nodules in the lungs, validating the decision made with CyPath® Lung’s results